Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Septerna, Inc. (SEPN)

Septerna Q2 2026 Revenue Rises to $26.7 Million; Net Loss Narrows to $13.0 Million

Positive Impact 3 of 5 earnings Written later

Septerna reported second-quarter 2026 results for the quarter ended June 30, 2026. Revenue rose to $26.7 million, almost all from the Novo Nordisk collaboration, and the net loss narrowed to $13.0 million from $24.8 million a year earlier, even as research and development expenses rose to $35.1 million. The company said its $516.5 million in cash is expected to fund operations at least into 2029, and it now expects Phase 1 data for SEP-479 in the first quarter of 2027.

Key points

  • Revenue of $26.7 million from the Novo Nordisk collaboration, compared with $0.1 million from Vertex in the second quarter of 2025.
  • Net loss of $13.0 million, or $0.29 per share, compared with $24.8 million, or $0.56 per share, a year earlier.
  • Research and development expenses of $35.1 million, up from $22.2 million; general and administrative expenses of $8.5 million, up from $6.9 million.
  • Cash, cash equivalents and marketable securities of $516.5 million at June 30, 2026, expected to fund operations at least into 2029.

The filing

CompanySepterna, Inc. (SEPN)
Form8-K, current report
Filed with the SECAug 10, 2026, 4:03 PM ET
Accession number0001193125-26-342328

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.